Last week, I blogged my opinion on the media’s reception and response to the iPrEx study that showed that in a trial of 2499 HIV negative men and transgendered women who were at high risk for HIV acquisition, those that received daily emtricitabine plus tenofovir (a combination drug) had a 44% reduction in HIV incidence […]
Irresponsible Journalism – PrEP for HIV
The New England Journal of Medicine today reported the results of a trial in which 2499 HIV-seronegative men or transgender women who were at high risk for HIV acquisition were enrolled to either receive daily emtricitabine plus tenofovir or placebo. The results were that those who received the anti-retroviral medications had a 44% reduction in HIV […]